Where FDA's peptide compounding dockets stand after July 2026

Two separate FDA compounding dockets advanced in July 2026, and as of 1 August neither has produced a final agency decision. On 30 July the comment period closed on FDA's proposal not to include semaglutide, tirzepatide and liraglutide on the 503B Bulks List (Docket FDA-2018-N-3240). A week earlier, on 23–24 July, the Pharmacy Compounding Advisory Committee met to consider seven nominated peptide bulk drug substances for the separate 503A Bulks List (Docket FDA-2025-N-6895). Both are now in the same procedural posture: the record is closed or the advice has been given, and FDA has published no determination on either. Any account describing either outcome as settled is running ahead of the record.

What closed on 30 July?

FDA published the underlying notice on 1 May 2026 (91 FR 23431), proposing not to add the three GLP-1 receptor agonist substances to the 503B Bulks List — the list of bulk substances that registered outsourcing facilities are permitted to compound from. The agency's stated reasoning turned on the statutory "clinical need" standard: FDA concluded that nominators had not identified an attribute of the approved products making them medically unsuitable for identifiable patients, and it distinguished clinical need from prescriber or patient preference.

The original deadline was 30 June 2026. On 26 June FDA extended it by 30 days (91 FR 38719), moving the close to 30 July 2026. That extension is why a number of secondary trackers still carry the June date; the June notice supersedes it.

The next step belongs to FDA. The May notice states that the agency will consider the comments received, may seek advisory committee input, and will publish a final determination in the Federal Register. It does not commit to a date, and FDA has not announced one.

What did the advisory committee actually do?

The 23–24 July meeting was noticed in the Federal Register on 16 April 2026 under Docket FDA-2025-N-6895. The committee considered BPC-157, KPV, TB-500 and MOTS-c related bulk drug substances on the first day, and emideltide (DSIP), Semax and epitalon related substances on the second, in each case with free base and acetate forms evaluated separately.

As of this writing FDA has not posted minutes, summary minutes, or vote tallies for that meeting. Several secondary sites have published specific vote counts. Those figures could not be verified against any FDA-published document and are therefore not reproduced here. It is also worth restating what a committee vote would and would not mean: by FDA's own description, advisory committees make non-binding recommendations, which the agency generally follows but is not legally bound to follow. A favorable vote is not a listing.

Why does the 503A and 503B distinction matter here?

The two lists govern different actors under different legal tests. Section 503A concerns compounding by licensed pharmacists and physicians for identified patients; section 503B concerns registered outsourcing facilities compounding at larger scale without patient-specific prescriptions. A substance can stand differently on each list. The July activity is often compressed into "FDA moved on peptides", which flattens two dockets with different statutory standards, different nominators and different consequences into a single storyline.

For laboratory suppliers, neither docket changes anything directly. Compounding lists govern what may be compounded into drug products for administration to patients. They do not describe research-grade material sold for in-vitro laboratory research, which is what Veridian Research supplies, and which is not for human or veterinary use. The dockets matter as an indicator of regulatory attention and of where documentation expectations are heading — not as a change in what a research supplier may ship.

What is worth watching next?

Three developments are checkable rather than speculative: publication of a final determination on Docket FDA-2018-N-3240 in the Federal Register; posting of PCAC minutes for the July meeting; and any revision to FDA's published 503A and 503B bulk drug substance category lists. Each has a primary source, and each should be read from that source rather than from a secondary tracker. None had appeared as of 1 August 2026.